The US Oncology Network
Association
Location:
The Woodlands, TX,
United States (USA) (US)
ISNI: 0000000404125468
ROR: https://ror.org/05xc20j70
Neoadjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy, followed by adjuvant pembrolizumab versus placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses from KEYNOTE-522 (2022)
Schmid P, Cortes J, Dent R, Pusztai L, Mcarthur H, Kuemmel S, Bergh J, et al.
Conference contribution
KEYNOTE-522: Neoadjuvant Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy Followed by Adjuvant Pembrolizumab vs Placebo for Early-stage Triple Negative Breast Cancer (2022)
Mcarthur H, Cortes J, Dent R, Pusztai L, Kuemmel S, Bergh J, Denkert C, et al.
Conference contribution
Results from CONTESSA: A phase 3 study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2-, hormone receptor plus (HR plus ) metastatic breast cancer (MBC) who have previously received a taxane (2021)
O'Shaughnessy J, Schwartzberg L, Piccart M, Rugo HS, Yardley DA, Cortes J, Untch M, et al.
Conference contribution
Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma (2016)
Crump M, Leppa S, Fayad L, Lee JJ, Di Rocco A, Ogura M, Hagberg H, et al.
Journal article